Table 242 Multivitamin supplements and colorectal cancer risk. Main characteristics of studies excluded from the CUP SLR meta-analysis Cases/ Author, Year, Study name, Study size Case Exposure RR (95%CI) Adjustment Reasons for WCRF Code, Outcome Comparison characteristics Follow-up ascertainment assessment Ptrend factors exclusion Country (years) 214/ Mortality, colon 105 500 use vs no use 1.52 (1.03-2.27) JACC, cancer, men Municipal 15 years Prospective Iso, 2007 resident FFQ Cohort, Age, centre Outcome is 179/ use vs no use 1.42 (0.92-2.19) COL40707 registration Age: 40-79 location mortality Japan records, death Multivitamin Mortality, rectal years, 159/ certificates use vs no use 1.09 (0.64-1.86) M/W cancer, men 84/ Women use vs no use 0.96 (0.41-2.24) NHS, Nested Case 39% and 36% Feskanich, 2004 193/ Medical records Incidence, Month of blood Superseded by Control, users in cases COL01680 383 controls and writing or FFQ colorectal user vs non-user draw, year of Fuchs, 2002 Age: 46-78 and non-cases USA 11 years by telephone cancer, birth COL00415 years, respectively W Age, family history of Vitamin E HPFS, colorectal supplement and Prospective cancer, BMI, 0.82 (0.60-1.11) multivitamin Not enough Hospital and Cohort, physical Wu, 2002 328/ Incidence, vs never studies to FFQ pathology Age: 40-75 activity , COL00905 47 344 cancer, no past users conduct analysis Multivitamins years, of reports National USA 10 years users on colon cancer and individual M, smoking before Death Index Multivitamin only vitamins 0.97 (0.75–1.24) Health age 30, aspirin only users vs professionals use , red meat never users intake, alcohol consumption Hospital and Fuchs, 2002 NHS, 428/ FFQ Incidence, colon Age, alcohol Not enough yes vs no 0.89 (0.72-1.10) COL00415 Prospective 88 758 pathology Multivitamin cancer, no consumption, studies to
Table 242 Multivitamin supplements and colorectal cancer risk. Main characteristics of studies excluded from the CUP SLR meta-analysis Author, Year, WCRF Code, Country Study name, characteristics Cases/ Study size Follow-up (years) Case ascertainment Exposure assessment Outcome Comparison RR (95%CI) Ptrend Adjustment factors Reasons for exclusion Iso, 2007 COL40707 Japan JACC, Prospective Cohort, Age: 40-79 years, M/W 214/ 105 500 15 years Municipal resident registration records, death certificates FFQ Multivitamin Mortality, colon cancer, men use vs no use 1.52 (1.03-2.27) Age, centre location Outcome is mortality 179/ use vs no use 1.42 (0.92-2.19) 159/ Mortality, rectal cancer, men use vs no use 1.09 (0.64-1.86) 84/ Women use vs no use 0.96 (0.41-2.24) Feskanich, 2004 COL01680 USA NHS, Nested Case Control, Age: 46-78 years, W 193/ 383 controls 11 years Medical records and writing or by telephone FFQ Incidence, colorectal cancer, user vs non-user 39% and 36% users in cases and non-cases respectively Month of blood draw, year of birth Superseded by Fuchs, 2002 COL00415 Wu, 2002 COL00905 USA HPFS, Prospective Cohort, Age: 40-75 years, M, Health professionals 328/ 47 344 10 years Hospital and pathology reports National Death Index FFQ Multivitamins and individual vitamins Incidence, cancer, no past users Vitamin E supplement and multivitamin vs never users Multivitamin only users vs never users 0.82 (0.60-1.11) 0.97 (0.75–1.24) Age, family history of colorectal cancer, BMI, physical activity , of smoking before age 30, aspirin use , red meat intake, alcohol consumption Not enough studies to conduct analysis on colon cancer only Fuchs, 2002 COL00415 NHS, Prospective 428/ 88 758 Hospital and pathology FFQ Multivitamin Incidence, colon cancer, no yes vs no 0.89 (0.72-1.10) Age, alcohol consumption, Not enough studies to
CUP_colorectal_SLR_2016_RO.docx